UG

UNITED GUARDIAN INC - 10-K Summary (Fiscal Year Ended Dec 31, 2007)

Business Context and Reporting Period

This Annual Report (Form 10-K) covers the fiscal year ended December 31, 2007. United-Guardian, Inc. operates primarily through its Guardian Laboratories Division, focusing on the research, development, manufacturing, and marketing of cosmetic ingredients, personal care products, pharmaceuticals, and specialty industrial products. The Company's two largest product lines are the LUBRAJEL® line (cosmetic ingredients) and RENACIDIN® IRRIGATION (pharmaceutical), which together accounted for approximately 94% of sales in 2007.

A significant corporate event occurred on December 11, 2007, when the Company sold substantially all assets of its Eastern Chemical Corporation subsidiary to Pfaltz & Bauer, Inc. Eastern's operations are now reported as discontinued operations.

Key Financial Metrics

Note: The Company maintained a $2,000,000 line of credit with JPMorgan Chase Bank but had no outstanding balance as of March 1, 2008.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by 6.1% ($680,659) compared to 2006. This was driven by a 9.5% increase in Personal Care products (primarily LUBRAJEL) and a 5.6% increase in Pharmaceuticals (driven by a price increase).
• Discontinued Operations: The Company recognized a gain of $84,361 (net of tax) on the sale of the Eastern subsidiary. Eastern's 2007 operating income was $32,862.
• Cost Efficiency: Cost of sales as a percentage of revenue decreased from 44.4% to 40.8%, largely due to reduced raw material costs in the first three quarters of 2007.
• Inventory Reduction: Inventories decreased by approximately $601,000. This was primarily due to the liquidation of a large stockpile of RENACIDIN IRRIGATION built up in 2006 while awaiting FDA approval for a new manufacturing facility.
• Investment Income: Other income increased by 41.6% to $575,027, driven by higher investment income and gains on the sale of marketable securities.

Guidance, Outlook, and Risks

Management Commentary: Management expects 2008 R&D costs to be comparable to the last two fiscal years. The Company is actively developing new product lines, including LUBRAJEL II and LUBRASIL II, to recapture market share and expand applications. Sales of KLENSOFT, which declined 53% in 2007 due to a specific customer's buying patterns, rebounded in early 2008.

Pension Plan: The Company froze its defined benefit pension plan in late 2007 and initiated termination procedures in February 2008. This resulted in a significant actuarial gain and a shift from a pension liability to a pension asset on the balance sheet.

Risks and Contingencies:

• Customer Concentration: Two customers accounted for 52% of revenues in 2007. The largest marketing partner, ISP Technologies Inc., accounts for a significant portion of personal care sales.
• Regulatory Review: As of March 1, 2008, the NASD (National Association of Securities Dealers) was conducting a review of trading activity in the Company's stock from April to May 2007. The Company is cooperating, but the outcome is uncertain.
• Patent Expirations: The patent for RENACIDIN IRRIGATION expired in October 2007, though management does not anticipate a material impact on revenue.

Investor Verification Checklist

• Customer Concentration: Verify the stability of relationships with the top two customers, who represent over half of total revenue.
• Discontinued Operations: Confirm that no further liabilities or costs are associated with the sale of the Eastern subsidiary.
• Pension Termination: Monitor the progress of the pension plan termination and the associated cash flow impacts for 2008.
• NASD Inquiry: Track the status of the NASD investigation regarding trading activity in 2007.
• Inventory Levels: Ensure that inventory levels for RENACIDIN remain at normal operating levels following the 2006 buildup.